# Long-term effectiveness of thymectomy in late-onset myasthenia gravis

## TL;DR

This study finds that thymectomy may improve long-term outcomes in late-onset myasthenia gravis patients compared to medical treatment alone.

## Contribution

The study provides evidence that thymectomy may increase remission likelihood in late-onset myasthenia gravis patients.

## Key findings

- Thymectomy was associated with a 3.25-fold increased probability of disease remission in LOMG patients.
- Thymectomy may be a beneficial therapeutic option for LOMG without ongoing immunosuppressive therapy.

## Abstract

Thymectomy is a well-established treatment in anti-AChR generalized myasthenia gravis (gMG) patients aged 18–50 years. However, the MGTX trial failed to prove an additional benefit of thymectomy in late-onset MG (LOMG) patients and studies conducted so far have shown controversial results. The primary aim of this study was to assess the safety and effectiveness of thymectomy in LOMG patients compared to medical therapy alone.

This was an observational retrospective case–control study of LOMG patients followed at the MG Clinic of Pisa University Hospital from 1996 to 2024. Inclusion criteria were: diagnosis of non-thymomatous gMG with anti-AChR antibodies; age at onset ≥ 50 years, and minimum follow-up of 12 months. The cumulative incidence of disease remission between the thymectomy and the conservative group was compared with Kaplan–Meier analysis with log-rank test and the Cox regression model was used to estimate the effect of thymectomy on achieving remission after adjustment for confounding variables.

Among our population of 127 LOMG patients, 87 patients underwent thymectomy, while 40 patients received medical treatment only. When evaluating neurological outcomes at the last follow-up, the thymectomy group had a 3.25-fold (HR = 3.25, 95% CI 1.31–8.1) increased probability of achieving disease remission than the conservative group, after adjustment for confounding variables.

Our findings suggest that thymectomy may be a feasible and potentially beneficial therapeutic option in this MG subgroup, possibly increasing the likelihood of disease remission without ongoing immunosuppressive therapy.

The online version contains supplementary material available at 10.1007/s00415-025-13424-2.